Thyroid function in children and adolescents with Hashimoto’s thyroiditis after l-thyroxine discontinuation

Giorgio Radetti1, Mariacarolina Salerno2, Chiara Guzzetti3, Marco Cappa4, Andrea Corrias5, Alessandra Cassio6, Graziano Cesaretti7, Roberto Gastaldi8, Mario Rotondi9, Fiorenzo Lupi1, Antonio Fanolla10, Giovanna Weber11 and Sandro Loche3

1Pediatrics, Regional Hospital, Bolzano, Italy  
2Pediatrics, University Federico II, Naples, Italy  
3Pediatric Endocrinology, Ospedale Pediatrico Microcitemico ‘A. Cao’ – AOB Cagliari, Cagliari, Italy  
4Pediatric Endocrinology, Bambino Gesù Children Hospital, Roma, Italy  
5Divisione di Endocrinologia Pediatrica, Ospedale Infantile Regina Margherita, Torino, Italy  
6Department of Pediatrics, University of Bologna, Bologna, Italy  
7Department of Pediatrics, University of Pisa, Pisa, Italy  
8Paediatric Department, Gaslini Hospital, Genova, Italy  
9Unit of Internal Medicine and Endocrinology, Fondazione Salvatore Maugeri I.R.C.C.S., ISPESL Laboratory for Endocrine Disruptors, University of Pavia, Pavia, Italy  
10Department of Biostatistics, Regional Hospital, Bolzano, Italy  
11Department of Pediatrics, Vita-Salute San Raffaele University, Milan, Italy

Abstract

Objective: Thyroid function may recover in patients with Hashimoto’s thyroiditis (HT).

Design: To investigate thyroid function and the need to resume l-thyroxine treatment after its discontinuation.

Setting: Nine Italian pediatric endocrinology centers.

Patients: 148 children and adolescents (25 m and 123 f) with HT on treatment with l-thyroxine for at least one year.

Intervention and main outcome measure: Treatment was discontinued in all patients, and serum TSH and FT4 concentrations were measured at the time of treatment discontinuation and then after 2, 6, 12 and 24 months. Therapy with l-thyroxine was re-instituted when TSH rose >10 U/L and/or FT4 was below the normal range. The patients were followed up when TSH concentrations were between 5 and 10 U/L and FT4 was in the normal range.

Results: At baseline, TSH was in the normal range in 139 patients, and was between 5 and 10 U/L in 9 patients. Treatment was re-instituted after 2 months in 37 (25.5%) patients, after 6 months in 13 patients (6.99%), after 12 months in 12 patients (8.6%), and after 24 months in an additional 3 patients (3.1%). At 24 months, 34 patients (34.3%) still required no treatment. TSH concentration >10 U/L at the time of diagnosis was the only predictive factor for the deterioration of thyroid function after l-thyroxine discontinuation.

Conclusions: This study confirms that not all children with HT need life-long therapy with l-thyroxine, and the discontinuation of treatment in patients with a TSH level <10 U/L at the time of diagnosis should be considered.

Key Words
► Hashimoto’s thyroiditis
► children
► l-thyroxine treatment
► subclinical hypothyroidism
► autoimmune thyroiditis

Correspondence should be addressed to G Radetti  
Email giorgio.radetti@gmail.com
Introduction

Hashimoto's thyroiditis (HT) is a frequent autoimmune disease that may present with a spectrum of altered thyroid function ranging from thyrotoxicosis to overt hypothyroidism. Treatment with l-thyroxine (l-T4) is commonly started in patients with either subclinical (high TSH with normal fT4) or overt hypothyroidism (subnormal fT4 and increased TSH). There is no consensus on the timing to start or discontinue therapy based on TSH concentrations in children and adolescents (1, 2, 3), even if current recommendations indicate that treatment should be considered in patients with serum TSH >10U/L (4).

Rallison, in a 20-year follow-up study (5), showed that in a substantial number of patients thyroid function might remain unchanged or even normalize over the years. Recently, we could confirm these results in two follow-up studies (6, 7, 8), in agreement with other authors (9, 10) also showing a relatively stable condition in HT children and adolescents. However, it is not well understood who are the patients needing life-long treatment and who can discontinue therapy. Even testing for thyroid function recovery by means of TRH stimulation during treatment did not reach a general acceptance (11).

We hypothesized that some children with HT on treatment with l-T4 may no longer need it. Thus, this study was designed to investigate how many HT patients treated with l-T4 maintain a normal thyroid function after therapy discontinuation. In addition, we looked for potential predictive markers to aid in the decision to treat or stop therapy. To test this hypothesis, we discontinued treatment in a large group of children with HT and followed them closely for two years.

Subjects and methods

Subjects

The study was performed between May 2011 and September 2013. The study group was comprised of 149 consecutive patients (26 males and 123 females) attending the outpatient clinics of nine Italian pediatric endocrinology centers. The patients were all born at full-term and not obese. The diagnosis of HT was made at a mean chronological age of 9.67 ± 2.65 years and was based on the presence of thyroid peroxidase antibody (TPOAb) and/or thyroglobulin antibody (TGAb), together with the typical ultrasound pattern. All the children had been treated with l-T4 for more than 1 year (4.1 ± 2.6; range 1–12 years). Not all children started treatment at diagnosis, because they were still euthyroid, but only later, during the follow-up, based on the thyroid function tests. TSH concentrations at diagnosis ranged from 5.0 to >1000U/L (37.9 ± 121.4). Free T4 was within the normal range in 84 patients (57%), and below the normal range in 64 (43%). Seven patients had celiac disease and 2 had vitiligo. No patients were affected with Turner or Down’s syndrome. A positive family history for autoimmune diseases was present in 71 (47.7%) of the patients. The study protocol followed the ethical principles outlined by the Helsinki Declaration. All protocols were approved by Partners Institutional Review Board. Written informed consent was obtained from all participants.

Study design

The children were admitted to the ward after an overnight fast for auxological evaluation. In all children, a blood sample was taken for measurement of serum fT4, TSH, thyroid peroxidase antibodies (TPOAb), thyroglobulin antibodies (TGAb), glucose, insulin, total and HDL cholesterol, and triglycerides. Chemokine CXCL10 was also measured in a subset of 35 subjects. Insulin sensitivity was evaluated with QUICKI = 1/(log(I0)+log(G0)), where I0 is the fasting insulin and G0 is the fasting glucose (12). A thyroid ultrasound was performed in all subjects.

Therapy with l-T4 was discontinued within 2 weeks, halving the dose in the first and in the second week. TSH and fT4 were measured after 2, 6, 12 and 24 months. In the 64 subjects with subnormal fT4 and/or TSH concentrations >100U/L at diagnosis, thyroid function was checked after 1 month, and the parents were instructed how to verify the presence of signs/symptoms of hypothyroidism. Treatment with l-T4 was restarted when TSH rose >10U/L and/or fT4 decreased below the normal range. Monitoring and follow-up were continued in subjects with TSH concentrations between 5 and 10U/L and a normal fT4. After 12 months, all auxological parameters were re-evaluated along with measurement of serum glucose, insulin, total and HDL cholesterol, triglycerides and QUICKI. Thyroid ultrasound was also repeated.

Methods

Anthropometric evaluation The children were admitted to the ward in the morning. All underwent an
anthropometric assessment including height, weight and pubertal stage evaluation. Standing height was measured using a wall-mounted Harpenden stadiometer. Weight was obtained with a traditional balance scale to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m²). Height and BMI were then expressed as standard deviation score (SDS) according to the Italian standards (13). The patients were classified as prepubertal or pubertal according to the standard Tanner's criteria (G1, G2–G5 for males and B1, B2–B5 for females) (14).

**Thyroid ultrasound** Ultrasound was performed in each center by the same observer, who was well trained in thyroid imaging, using a 7.5 MHz transducer. The volume of the thyroid gland was calculated using the formula for a prolate ellipse: Volume = 0.5 × (L × D × W) where L is the length, D is the anterior–posterior depth and W is the transverse width of the gland. Typical ultrasound findings for a diagnosis of Hashimoto's thyroiditis are a hypoechogenic signal with a dyshomogeneous structure. The alterations of echogenicity and homogeneity of the parenchyma were further quantified according to a pediatric scoring system (15): score 0: normal, score 1: mild parcelled hypoechogenicity, score 2: severe parcelled hypoechogenicity, score 3: mild generalized hypoechogenicity, score 4: severe generalized hypoechogenicity, score 5: near-anechogenicity. We refer to this score system throughout the manuscript as thyroid score (TS).

**Assays** Serum glucose was measured with automatic analyzers, using a hexokinase enzymatic method. Serum insulin was measured with an immunoradiometric assay (Immuvite 2000 Insulin, DPC, LA, CA), with an intra- and inter-assay CV of 8.3% and 8.6%, respectively. Total and HDL cholesterol and triglycerides were measured enzymatically by an automatic photometric method (Olympus Diagnostica Gmbh, Lismeehan, O'Callaghan's Mills Co. Clare, Ireland). TSH was measured by a chemiluminescent immunometric assay (Olympus Diagnostica Gmbh, Lismeehan, O'Callaghan's Mills Co. Clare, Ireland). TSH was measured enzymatically by an automatic photometric method (Roche Diagnostics). TSH was measured by a chemiluminescent immunometric assay (Roche Diagnostics); the intra- and inter-assay CV were 2.7% and 3.2%, respectively, and the sensitivity limit was 0.005 U/L. Measurement of fT4 was performed by chemiluminescent immunometric assay (Roche Diagnostics); the intra- and inter-assay CV were 1.8% and 2.6%, respectively, and the sensitivity limit was 0.3 pmol/L. Anti-thyroglobulin antibodies (TGAb) were measured by a chemiluminescent immunometric assay (Immuvite 2000 Anti-TG Ab, DPC, LA, USA) with an intra- and inter-assay CV of 3.2% and 4.6%, respectively, with a sensitivity limit of 2.2 U/mL. Anti-thyroid peroxidase antibodies (TPO-Ab) were measured by chemiluminescent immunometric assay (Immuvite 2000 Anti-TG Ab, DPC, LA, USA) with an intra- and inter-assay CV of 5.2% and 3.2%, respectively, and a sensitivity limit of 5 U/mL. The concentrations of CXCL10 in the patients' serum were measured using commercially available kits (R&D Systems). The mean minimum detectable dose of CXCL10 was 1.67 pg/mL. The intra- and inter-assay coefficients of variation were 3.0% and 6.1%, respectively. Samples were assayed in duplicate. Quality control pools for low, normal or high concentrations were included in each assay.

**Statistical analysis**

Data are shown as mean ± s.d. Differences between baseline and 12 months in the auxological and laboratory data were evaluated by the paired t-test. Two-way mixed ANOVA analysis was used to evaluate the effects of the between- and within-subjects variable and the two-way interactions. Variable for the within-subjects analysis was the time when TSH was measured (diagnosis, stop treatment, and 2 months after discontinuing the treatment). Variables considered for the between-subjects analysis were auxological data, goiter volume, degree of hypoechogenicity, TPOAb, TGAb, fT4 and CXCL10. Simple effects comparisons for the interaction were evaluated with the differences of least-squares means (Tukey-Kramer adjustment).

Logistic regression with ROC curve was used to assess whether TSH serum level at diagnosis could predict a TSH level >10 U/L, 2 months after stopping therapy. A P value of less than 0.05 indicates statistical significance. The StatView statistical software 4.3 (SAS Institute Inc., Cary, NC, USA) was used for these analyses.

**Results**

Serum TSH concentrations throughout the study are shown in Fig. 1. At the time of diagnosis, TSH ranged from 5 to >1000 U/L and in 64 (42.9%) of them it was <10 U/L. At baseline before l-T4 discontinuation, TSH was <5 U/L in all except 9 patients. Two months following discontinuation of treatment, TSH rose >10 U/L in 37 patients (25.3%, 5 dropped out during follow-up). After 6 months, 13 more patients showed a TSH >10 U/L.
(9.1% or 13/143). After 12 months, 12 more subjects (12/140, 8.6%, 3 more lost) had a TSH >10 U/L. After 24 months, 3 more subjects (3/99 3.1%, 41 lost) had a TSH >10 U/L.

At 12 months, a TSH between 5 and 10 U/L was observed in 25/140 patients (17.9%), while 53/140 patients (37.9%) had a TSH <5 U/L.

At 24 months, 9/99 patients (9.1%) had a TSH between 5 and 10 U/L, and 25/99 (25.5%) <5 U/L.

Altogether, 1 year after discontinuation of l-T4 78/140 (55.7%, 8 patients were lost during follow-up) and after 2 years 34/99 (34.3%, 49 patients lost during follow-up) still required no treatment.

The patients lost to follow-up were excluded from the statistical analysis. They were lost mainly because of poor compliance; none had biochemical and/or clinical evidence of hypothyroidism. We looked for possible differences between the patients who required resuming treatment (#62) and those who did not (#78), and the results are shown in Table 1. Patients who restarted treatment were younger and showed significantly higher TSH and TGAb concentrations at the time of diagnosis, and higher concentrations of TPOAb and goiter at baseline.

To verify whether a state of subclinical hypothyroidism might have exerted a negative influence during the first 12 months of the study, we evaluated the auxological parameters and the biochemical profile at baseline and after 12 months in 49 subjects who completed the study and for whom all data were available. No significant differences were found for the auxological parameters, lipid profile, glycaemia, insulin serum concentrations and insulin sensitivity (QUICKI) (Table 2). Furthermore, no significant changes were found in goiter frequency (39% vs 28%; NS), TS (2.52 ± 1.23 vs 2.36 ± 1.12; NS), TPOAb (698 ± 889 vs 366 ± 402 U/mL; NS), and TGAb (583 ± 934 vs 365 ± 606 U/mL; NS).

![Image](image_url)

**Figure 1**
Serum TSH concentrations at diagnosis, at baseline and after discontinuation of l-thyroxine.

**Table 1**
Clinical and hormonal characteristics in the group of patients who restarted treatment (group A) and in those who remained without treatment (group B) at diagnosis and at baseline.

<table>
<thead>
<tr>
<th>Group</th>
<th>Diagnosis</th>
<th>Baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age (years)</td>
<td>TSH (U/L)</td>
</tr>
<tr>
<td>Group A (#62)</td>
<td>9.67 ± 2.65</td>
<td>67.06 ± 177.2</td>
</tr>
<tr>
<td>Group B (#78)</td>
<td>11.01 ± 2.37</td>
<td>14.59 ± 14.14</td>
</tr>
</tbody>
</table>

P <0.05
NS

Table 2
Serum TSH concentrations at diagnosis, at baseline and after discontinuation of l-thyroxine.
Table 2  Auxological and biochemical profile of the 78 patients who remained without treatment (group B) at baseline and after 12 months.

<table>
<thead>
<tr>
<th></th>
<th>Height (SDS)</th>
<th>BMI (SDS)</th>
<th>Glucose (mg/dL)</th>
<th>Insulin (µL/L)</th>
<th>QUICKI</th>
<th>Total-C (mg/dL)</th>
<th>HDL-C (mg/dL)</th>
<th>Triglycerides (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>-0.008 ± 1.03</td>
<td>-0.11 ± 1.03</td>
<td>79.6 ± 6.6</td>
<td>6.9 ± 7.0</td>
<td>0.4 ± 0.0</td>
<td>163.5 ± 28.5</td>
<td>59.9 ± 13.7</td>
<td>72.6 ± 28.5</td>
</tr>
<tr>
<td>12 months</td>
<td>0.004 ± 0.91</td>
<td>-0.09 ± 0.99</td>
<td>79.7 ± 7.7</td>
<td>7.0 ± 4.2</td>
<td>0.4 ± 0.0</td>
<td>163.1 ± 25.0</td>
<td>57.5 ± 12.2</td>
<td>71.2 ± 21.8</td>
</tr>
<tr>
<td>P</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

HDL-C, high-density cholesterol; Total-C, total cholesterol.

TSH serum level at diagnosis was the only significant predictor of thyroid dysfunction after 2 months. We also found a significant correlation between TSH serum concentrations at diagnosis and those measured 2 months after stopping treatment (P < 0.01) (Fig. 2). ROC analysis showed that a patient with a TSH value at diagnosis <10 U/L had 79% probability of not developing thyroid dysfunction after discontinuation of treatment.

Discussion

The aim of our study was to investigate whether children and adolescents with HT actually treated with l-thyroxine should be treated lifelong. We have previously shown that thyroid function can change over time, and that it improves or even normalizes in a significant number of patients (6, 7, 8).

In the present study we have shown that two years after discontinuation of l-T4, 25.3% of the patients had a normal thyroid function, while 9.1% showed mildly elevated TSH concentrations with normal FT4. At variance with adults, this condition of subclinical hypothyroidism or ‘isolated hyperthyrotropinemia’ does not cause any clinical consequence on growth (6, 7, 8) and cognitive function (16) in children and adolescents. In this study, we confirm the relative safety of a mild TSH elevation, since we have not observed any adverse effect during the first 12 months of follow-up on growth, lipid profile, glucose homeostasis, and the development or worsening of goiter.

A recent study suggests that long-standing subclinical hypothyroidism may be associated with decreased concentrations of HDL cholesterol, but normal concentrations of triglycerides, total cholesterol and LDL cholesterol in children and adolescents (17). However, the patients of this study had an idiopathic form of hypothyroidism; therefore, differences in the cause of subclinical hypothyroidism, and in the duration of thyroid dysfunction, might all account for the discrepancies (18). On the other hand, the results of clinical trials with l-T4 have shown no beneficial effect on the lipid profile in patients with subclinical hypothyroidism. Increased insulin resistance has also been described in some studies (19, 20, 21) but not in others (22).

We believe that our preliminary findings are of clinical relevance in the management of children with HT. HT, however, is a chronic autoimmune disease and, as such, it may worsen with time and/or associate with other endocrine and non-endocrine disease. We previously showed that the presence of celiac disease, elevated TSH and TPOAb at diagnosis, and a progressive increase in TSH are predictive factors for thyroid failure in these patients (7). A continuous surveillance, not only of thyroid function, is thus mandatory. Thyroid ultrasound is particularly important, for the early detection of nodules, which seem to be more common than in the normal population (23), as well as for the assessment of thyroid volume. Furthermore, thyroid ultrasound may also reveal eventual modifications of thyroid volume in patients either on treatment or without treatment, also in euthyroid patients (24).

Figure 2

Effect plot obtained by logistic regression analysis showing the value (95% confidence limits) of serum TSH concentrations at diagnosis in predicting the probability of not requiring re-institution of treatment 2 months after discontinuation of l-thyroxine.
In order to identify the predictive factors which might aid in the decision of discontinuing treatment, we looked at parameters of disease activity such as antithyroid antibodies, the presence of goiter, the degree of hypoechogenity, and the concentrations of serum TSH, and fT4. TSH serum concentrations at diagnosis <10U/L confers a 79% probability that re-institution of treatment will not be required. The high predictive value of TSH is further supported by the significant correlation between serum TSH at diagnosis and at 2 months after discontinuation of treatment. This suggests that there may be different degrees of severity of the disease and, although minor changes may be observed, patients tend to maintain the same degree of thyroid dysfunction. Our findings support this hypothesis, since the patients who restarted treatment showed a more severe form of HT at diagnosis as well as at baseline. In fact, in these patients the diagnosis was made at a younger age and their thyroid function was more severely affected, with higher concentrations of TPOAb and TGAb, and a more frequent presence of goiter. These findings are in agreement with those of Wasniewska and coworkers (25) who reported that l-T4 treatment does not influence the natural history of the disease. Reports in the adult population seem to support our findings of relative stability of subclinical hypothyroidism over time. Long-term follow-up studies show that although 5–8% per year of patients became frankly hypothyroid (26, 27, 28, 29, 30), 6–35% per year show normalization of thyroid function.

We also measured chemokine CXCL10 as an index of autoimmune inflammation in a subset of patients. CXCL10 (a prototype Th1-oriented immunophenotype chemokine) plays a role in the initiation of HT and contributes to maintaining chronic autoimmune inflammation. It has been shown that CXCL10 is closely related to a more severe course of HT with development of hypothyroidism (31, 32, 33). CXCL10 concentrations, however, were not different between groups.

Furthermore, regional differences in iodine concentration should not have influenced our results since a study reported no differences among the centers participating in the study (34).

Our results suggest that a substantial number of children with HT on treatment with l-T4 do not require lifelong treatment. Since TSH at diagnosis was a strong predictive factor of thyroid function, we suggest discontinuation of treatment in children with a TSH level at diagnosis <10U/L. The absence of any clinical adverse effect after discontinuation of treatment supports this suggestion. Nonetheless, prolonged surveillance of thyroid function and morphology is required.

A weakness of our study is represented by the large number of patients lost to follow-up, mainly because of lack of compliance and not because symptomatic of hypothyroidism. However, their auxological characteristics and their thyroid function and morphology were similar to those who completed the study.

In conclusion, we have shown that LT4 treatment may be discontinued in some patients with HT. When and at which TSH serum level the treatment should be restarted remain a matter of debate, and require further studies.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References


Received in final form 24 March 2017
Accepted 27 March 2017
Accepted Preprint published online 27 March 2017